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ABSTRACT
Introduction: Chronic kidney disease (CKD) represents a huge burden in patients with type 2 diabetes
(T2DM). This review therefore has the aim of assessing the add-on value of new glucose-lowering
agents compared or combined with inhibitors of the renin angiotensin aldosterone system (RAAS) on
renal outcomes in T2DM patients.
Areas covered: This article first summarizes the results reported with RAAS inhibitors, mainstay of
nephroprotection in T2DM with albuminuria. Second, it describes the positive results with glucagon-like
peptide-1 receptor agonists (GLP-1RAs) and, even more impressive, sodium-glucose cotransporter type
2 inhibitors (SGLT2is). Third, besides the potential of combined therapies, it briefly considers some new
approaches currently in development.
Expert opinion: RAAS inhibitors exert renoprotective effects beyond their blood pressure lowering
effects while SGLT2is, and possibly GLP-1RAs, exert nephroprotection independently of their glucose-
lowering activity. These effects were demonstrated not only on surrogate endpoints such as albumi-
nuria and estimated glomerular filtration rate decline, but also on hard endpoints, including progres-
sion to end-stage renal disease requiring replacement therapy. The underlying mechanisms are
different and potentially complementary on glomerular hemodynamics, arguing for combined thera-
pies. Nevertheless, there is still room for new emerging drugs to tackle CKD in T2DM.
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Chronic kidney disease (CKD) is a classical complication of
diabetes mellitus, which may lead to end-stage renal disease
(ESRD) [1]. Its pathophysiology is more complex in type 2
diabetes (T2DM) than in type 1, especially because of the
intervention of several other risk factors beyond chronic
hyperglycemia: arterial hypertension, abdominal obesity, dys-
lipidemia, hyperuricemia, which all are associated with insulin
resistance, low-grade inflammation and oxidative stress [2,3].
Globally, the burden of diabetes and hypertension considered
as the two leading drivers of CKD has increased dramatically
worldwide over the past several decades. The number of
patients with known diabetes quadrupled between 1980 and
2014 while the number of adults with elevated blood pressure
almost doubled between 1975 and 2014. Globally, CKD due to
diabetes and CKD due to hypertension contributed to about
half and near a quarter of the overall increase in CKD disabil-
ity-adjusted-life-years, respectively [4]. Hypertension and dia-
betes are coexisting in the vast majority of patients with
T2DM. Making a clear distinction between these two entities
(patient primarily hypertensive or diabetic) might be difficult
but pragmatically little relevant from a therapeutic point of
view. This is illustrated by the fact that a kidney biopsy to
prove diabetic nephropathy was not required in all large trials
that will be discussed hereafter. The annual incidence of
microalbuminuria and albuminuria in patients with T2DM
averaged ~ 8%, with an incidence of developing estimated
glomerular filtration rate (eGFR) using the Modification of Diet
on Renal Disease (MDRD) equation – < 60 ml/min/1.73 m2
estimated to be ~ 2–4% per year and an annual incidence of
ESRD ranging from 0.04% to 1.8% [5]. Over the last two
decades, the prevalence of CKD is increasing in patients with
T2DM, a paradoxical effect of the better management of
cardiovascular risk factors that increases life expectancy in
this high-risk population [6]. Thus, both the prevention and
early appropriate management of CKD in patients with T2DM
currently represents a major challenge [7,8].
Tight glucose control is the first step to prevent microan-
giopathy, whose early renal biological marker is the develop-
ment and progression of albuminuria [9]. Evidence also
suggests that it can ameliorate eGFR loss and possibly pro-
gression to ESRD, yet these benefits appear to be most pro-
nounced when applied to T2DM patients with the early stages
of CKD [10]. However, tight glucose control is not easy to
reach and maintain in many T2DM patients, requires long-
term follow-up to prove its efficacy on hard clinical endpoints
and may be insufficient to improve renal outcomes, especially
when CKD is already present [11]. Furthermore, CKD may alter
the pharmacokinetic parameters of several glucose-lowering
agents, an effect that renders their use more difficult or even
contraindicated in clinical practice [12,13].
Lowering arterial blood pressure also reduces renal events
in patients with T2DM [14]. This effect may be additive to the
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positive effect of intensive glucose control as shown in the
ADVANCE trial that tested both strategies [15]. Inhibition of
the renin-angiotensin-aldosterone system (RAAS) has proven
its ability to prevent and slow down the progression of CKD in
diabetic patients, an effect being partially independent of the
effect on arterial blood pressure [16]. The benefit is particularly
prominent in patients with micro- or macro-albuminuria.
According to a network meta-analysis comparing efficacy
and safety of blood-pressure lowering agents in adults with
diabetes and CKD, RAAS inhibitors were the most effective
strategies against ESRD [17].
As add-on therapy, new glucose-lowering agents, especially
sodium-glucose cotransporter type 2 inhibitors (SGLT2is) [18–21],
showed beneficial renal outcomes in T2DM patients with estab-
lished cardiovascular disease [22,23]. Glucagon-like peptide-1
receptor agonists (GLP-1RAs) also showed positive effects on
composite renal outcomes in patients with T2DM [24,25]. These
newer glucose-lowering approaches seem to be promising for the
prevention and treatment of CKD in patients with T2DM, an effect
occurring beyond improvement of glucose control [13,26,27].
Increasing evidence showed that oxidative stress and low-
grade inflammation play a major role in diabetic complica-
tions; furthermore, renal fibrosis is an emerging entity that
contribute to the early development of diabetic kidney dis-
ease. These new concepts pave the road to innovative phar-
macological approaches currently in development [28,29]. The
notion of diabetic nephropathy as a purely vascular disease is
outdated and it has become clear that it is a multidimensional,
multicellular condition [29].
The aim of the present narrative review is to analyze the
effects of the different pharmacological therapies used to
prevent or retard the progression of CKD in patients with
T2DM. We will successively summarize (i) the effects of inhibi-
tors of the RAAS, the best validated pharmacological approach
regarding nephroprotection, (ii) describe the effects of new
glucose lowering agents that recently showed promising
results on surrogate and clinical renal outcomes, and finally
(iii) introduce future therapies currently in development that
target innovative mechanisms. As a main objective, the
respective add-on value of SGLT2is and GLP-1RAs on renal
outcomes will be discussed, both in comparison and in com-
bination with RAAS inhibitors.
2. Inhibitors of the renin-angiotensin-aldosterone
system
Blood pressure control is beneficial for both cardiovascular and
renal outcomes in T2DM patients [30,31], as it is clearly empha-
sized in different guidelines in the fields of nephrology [32],
diabetes [9], or hypertension [33]. More debated is whether the
target levels should be different in patients with and without
T2DM [33–36]. It is classically recognized that RAAS inhibition
therapies have potential added value compared with other
antihypertensive therapies in T2DM patients, especially in
patients with (micro)albuminuria [9,32,33]. However, even if
RAAS inhibitors have proven some superiority in terms of
renal outcomes compared to other antihypertensive agents
[17], we must keep in mind that more than one medication
will be necessary to adequately control arterial blood pressure
in a majority of T2DM patients with hypertension [37,38]. Of
note, although beyond the scope of this review paper devoted
to renal outcomes, RAAS inhibitors exert potential benefits on
other clinically relevant outcomes, notably by reducing the
incidence of major cardiovascular events [38–40].
RAAS inhibition can lead to renal protection in an indepen-
dent way of blood pressure control via different pathways. One
of the most important is certainly the effect of RAAS inhibitors
on the intraglomerular pressure. Indeed, RAAS inhibitors
decreased intraglomerular hypertension by limiting the vaso-
constriction of postglomerular arteriole induced by angiotensin
II (Figure 1). This effect will lead to a decrease in albuminuria
and, at long term, to beneficial effects on kidney function [41].
This so-called ‘hemodynamic’ effect also explains why starting
therapy with RAAS inhibitors frequently goes with an initial
slight increase in serum creatinine or decrease in eGFR. This
functional decrease in renal filtration is generally limited and
reversible. Other mechanisms of action have been suggested to
explain renal damage when the RAAS system is activated:
increased oxidative stress, endothelial dysfunction, promotion
of inflammation, mesangial cell proliferation, and transforming
growth factor beta (TGF-β) profibrotic effect [42,43] .
Tables 1 and 2 reviewed some important randomized con-
trolled trials (RCTs) comparing different RAAS inhibitors with
placebo or other antihypertensive therapies, respectively. We
will limit our analysis to studies with the largest samples (>
250 patients in each arm), focusing on patients with T2DM
and, if possible, reporting ‘hard’ clinical renal endpoints (i.e.
doubling of serum creatinine and/or ESRD, usually defined as
need for dialysis or renal transplantation).
2.1. Angiotensin converting enzyme inhibitors
The specific role of ACE inhibitors has been first studied in type 1
diabetic patients. It is considered nowadays as the classical therapy
for type 1 diabetic nephropathy, already from the early stage of
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kidney damage, that is, in patients with normal GFR but presence
of microalbuminuria [9]. By analogy, the indication of ACE inhibi-
tors in T2DM patients with albuminuria is now largely adopted,
even in absence of hypertension but presence of (micro-)albumi-
nuria [9]. However, most of the studies in patients with T2DMwere
performed in hypertensive patients. This potential confounding
factor makes the definitive proof of a positive blood pressure-
independent effect of ACE inhibitors more challenging. This is
particularly the case in comparative studies ‘versus placebo’, as
the RAAS inhibitor group has frequently a better control of blood
pressure. Most of the studies showed positive impacts on usual
surrogate markers such as change of proteinuria (or new onset of
albuminuria) and decline in GFR (or increase in serum creatinine).
Specific studies with renal ‘hard’ end-points in T2DM patients are
less numerous, and some of them are underpowered, with rather
few events because a baseline low risk (normal eGFR with no or
only marginal microalbuminuria) and/or with an insufficient fol-
low-up (Table 1). For instance, in the UKPDS study, despite a long
follow-up of 9 years, no significant differences could be detected
between captopril and atenolol when considering the progression
to microalbuminuria, macroproteinuria or ESRD (very few events);
indeed, these results were obtained in patients with newly diag-
nosed T2DM and hypertension, but normal kidney function and
low proportion of albuminuria at baseline, and reaching similar
blood pressure control with both antihypertensive medications
[44]. Two large prospective long-term trials, ALLHAT [45] and
ADVANCE [40], have reported data on renal endpoints, including
‘hard’ outcomes. In ALLHAT, an ACE inhibitor (lisinopril) was not
better than a diuretic (chlorthalidone, prespecified head-to head
comparison with statistical analysis) or a calcium channel blocker
(amlodipine, but no head-to-head prespecified statistical analysis)
on the renal composite outcomes (or the single endpoint ESRD)
(Table 1). The absence of significant difference in ESRD between
lisinopril and either chorthalidone or amlodipine was confirmed
after an extended follow-up of about 9 years in the diabetic
population of ALLHAT [46]. The impact of ALLHAT is, however,
limited by the absence of any data on albuminuria and by the fact
that the blood pressure control was different in the therapeutic
groups [45,46]. ADVANCE compared an association of perindopril
and indapamide versus placebo in patients with normal renal
function, and only a minority had micro- or macroalbuminuria
(25% and 3.5%, respectively) [40]. The composite renal outcome
was significantly better in the perindopril group than in the pla-
cebo group, but the results were mainly explained by the positive
effect on new onset of microalbuminuria, whereas the impact on
doubling serum creatinine or ESRD was not significant in this
population with a relatively low ESRD risk (Table 1). As in
ALLHAT, the results could be explained, at least in part, by
a better blood pressure control in the active group [14,40], but
possibly also by the concomitant prescription of indapamide,
a thiazide-like diuretic that showed some positive vascular and
renal effects [47].
Figure 1. Complementary renoprotective effects of RAAS inhibitors and SGLT2 inhibitors by targeting efferent (through blockade of angiotensin 2 vasoconstriction)
and afferent (through restoration of tubuloglomerular feedback) arterioles, respectively.
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In three other studies in T2DM patients with normal serum
creatinine levels (MICROHOPE, DIABHYCAR, PERSUADE), no
significant differences in the changes of serum creatinine or
in renal outcomes were reported when comparing an ACE
inhibitor with a placebo [39,48,49]. However, in MICROHOPE
(32% of T2DM patients with microalbuminuria at baseline) [39]
and in DIABHYCAR (74% of T2DM patients with microalbumi-
nuria and 26 % with macroalbuminuria at baseline) [48], the
rate of new onset of persistent macroalbuminuria was signifi-
cantly lower and the rate of regression from macro to micro or
from micro to normal albuminuria was numerically higher in
the ACE inhibitor group compared with the placebo group,
respectively. No data on albuminuria neither at baseline nor at
the end of the trial were available in PERSUADE, an analysis
that evaluated a large subgroup of T2DM patients from the
cardiovascular EUROPA study [49] (Table 1).
Several meta-analyses (however, most of them mixing
patients with type 1 and type 2 diabetes) support the use of
ACE inhibitors in diabetic patients with renal diabetic nephro-
pathy, especially in the presence of significant albuminuria
[34,50,51]. The specific (independent of any blood pressure
effect) added value of ACE inhibitors in the absence of albu-
minuria remains more debatable [52,53]. Also, data in T2DM
patients with low or very low GFR values are scarce [35].
2.2. Angiotensin II receptor antagonists
Evidence of the role of angiotensin II receptor antagonists (ARA
II) in T2DM patients is more robust than for ACE inhibitors. Two
big trials focusing on renal events (with no equivalent in terms of
patient characteristics and sample size for ACE inhibitors) are
available with ARA II in T2DM patients: IDNT [37] and RENAAL
[38] (Table 2). Both studies included a majority of hypertensive
patients with already advanced CKD (elevated mean serum crea-
tinine around 1.65 mg/dL and 1.9 mg/dL and significant (macro)
albuminuria around 1.9 g/day and 1.2 g/g in IDNT and RENAAL,
respectively) [37,38]. IDNT compared irbesartan versus placebo
versus amlodipine [37]. RENAAL compared losartan with placebo
[38]. In both studies, the reduction effect on albuminuria was
significantly better in the ARA II groups. Still more relevant, the
risk of renal composite outcomewas significantly lower with ARA
II compared with placebo (or even amlodipine). Also, the specific
risk of doubling serum creatinine was significantly lower with
ARA II in the two studies, whereas the reductions of the risk of
reaching ESRD were borderline in IDNT (p = 0.07) and significant
in RENAAL [37,38] (Table 2). This effect seems independent of
blood pressure control. Other studies comparing ARA II and
placebo focused on diabetic nephropathy, but in patients with
a baseline lower renal risk: normal (or near to normal) renal
function, well- controlled hypertension, and normoalbuminuria
(or only a slight proportion of microalbuminuria) [51,53]. If some
results suggest positive results in terms of albuminuria (notably
on the new onset of albuminuria), results are much less evident
in terms of ‘hard’ clinical endpoints in this population with less
advanced disease and at much lower risk to progress to ESRD, as
shown in the ROADMAP trial comparing olmesartan with pla-
cebo [54] (Table 2). In the Japanese study CASE-J evaluating
a subgroup of T2DM patients, the ARA II candesartan was
associated with a significantly lower rate of a composite renal
outcome compared with the calcium channel blocker amlodi-
pine after a follow-up of 3.3 years [55], thus confirming the
results of INDT that compared irbesartan with amlodipine
(Table 2). Unfortunately, no data on the albuminuria status at
baseline and during the study were reported in CASE-J trial [55].
The question of the superiority of ARA II compared to ACE
inhibitors has been debated for a long time, but today, most
authors agree on a similar effect of the two classes of RAAS
inhibitors. In a head-to-head comparative RCT in T2DM
patients with albuminuria, a similar effect on albuminuria
and GFR decline was observed with telmisartan and enalapril
[56]. The large trial ONTARGET, although not specifically dedi-
cated to T2DM patients (9612 diabetics among 25,620 patients
included) did not show any superiority in terms of renal end-
points (GFR decline, albuminuria) but also ‘hard’ endpoints
(such as doubling serum creatinine or reaching ESRD) of tel-
misartan compared with ramipril [57]. Also, pooled analyses,
including network meta-analyses, do not support any clear
superiority of ARA II over ACE inhibitors in T2DM patients
[34,50,52,58,59].
2.3. Dual blockade of RAAS
High-risk diabetic patients, as those included in the RENAAL or
IDNT studies, had a lower albuminuria with ARA II and a better
renal outcome, yet a rather high ‘renal residual risk’ may persist
[60]. Based on first results showing an additional decrease of
albuminuria with dual RAAS blockade [59], studies were carried
out in high renal risk patients with therapies combining an ACE
inhibitor and an ARA II (Table 3). ORIENT [61] compared renal
outcomes with ACE inhibitor plus olmesartan versus ACE inhi-
bitor plus placebo while VA-NEPHRON D [62] compared lisino-
pril plus losartan versus lisinopril plus placebo. Both studies
included T2DM patients with macroalbuminuria and moder-
ately decreased renal function. In both trials, a significantly
better control of albuminuria was observed, but with only
marginal effects on other renal outcomes (Table 3). Safety was
a concern with a higher risk of dialysis and hyperkalemia in the
combined therapy group [62] These data, and data from meta-
analyses, confirm the absence of clear added value of ACE
inhibitor- ARA II combined therapy on renal events [17,50].
A similar conclusion may be drawn for aliskiren a direct
renin inhibitor whose effect was investigated as add-on ther-
apy to an ARA II or an ACE inhibitor. Preliminary encouraging
results (better control of albuminuria in the aliskiren group
compared with placebo) were not confirmed in the largest
ALTITUDE study [63]. Even if patients had a slightly better
control of albuminuria, the effect was not significant on the
renal composite endpoint (and on secondary renal endpoints
such as doubling serum creatinine and ESRD) (Table 3).
Moreover, again safety was a concern, notably with
a significantly higher risk of hyperkalemia [63].
Another way to reinforce the RAAS blockade is to add an
aldosterone receptor blocker to either an ACE inhibitor or an
ARA II. Several studies have been performed with the classical
non-selective aldosterone antagonist spironolactone with
some positive results, as summarized in several meta-
analyses [64,65]. However, up to now, spironolactone has
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never crossed the border of limited sample size studies with
surrogate markers as endpoints (principally effect on albumi-
nuria). Reduction in albuminuria were also reported with two
other mineralocorticoid receptor antagonists eplerenone [66]
and finerenone [67]. Some concerns were reported with spir-
onolactone in terms of risk of hyperkalemia, an adverse event
that may occur more frequently in real life than in RCTs [68].
Thus, this association to protect renal function is not recom-
mended in clinical practice yet. Larger prospective trials are
underway, mainly with finerenone, a more selective nonster-
oidal mineralocorticoid receptor antagonist that might induce
less hyperkalemia [67,69].
2.4. Still for debate
Beyond their potential benefit on blood pressure control and
cardiovascular endpoints, ARA II are the drugs with the better
evidence of renal protection in T2DM patients with albumi-
nuria [37,38,70]. Because the evidence of a strong renal pro-
tection in type 1 diabetic patients with ACE inhibition [9], and
the absence of clear superiority of ARA II compared to ACE
inhibitors [9,56], both pharmacological classes are now equally
considered as ‘standard of care’ of diabetic nephropathy with
albuminuria, and this is clearly stated in several guidelines
[9,32,33,35]. Having said that, some points and ‘gray zones’
need to be briefly discussed. As already mentioned, the blood
pressure control is of main importance in T2DM patients and
this goal requires a combination of several different antihy-
pertensive agents in a majority of patients with CKD and
albuminuria [9]. The additional benefit of RAAS inhibitors,
beyond blood pressure control, is mainly proven in T2DM
patients with micro- and, still more, macro-albuminuria and
is more debatable in absence of (micro)albuminuria [9,32].
RAAS inhibitors reduce proteinuria, a risk marker for renal
disease progression and their antiproteinuric effect correlates
with their additional renal benefits [71]. Data emerged from
clinical trials demonstrating that use of ‘supratherapeutic
doses’ of RAAS inhibitors (doses greater than those approved
for lowering blood pressure), compared with standard doses,
has favorable efficacy in reducing proteinuria in T2DM patients
with CKD. Supratherapeutic dosing may be a valuable
approach for optimizing RAAS blockade and providing reno-
protection [72].
The benefit/risk ratio of this RAAS blocker therapy has been
questioned in patients older than 70 years (such aged patients
being excluded from large RCTs discussed above and presented in
Table 1–3), especially in people with relatively preserved GFR and
low albuminuria [73]. Renal safety (risk of hyperkalemia and acute
renal failure) remains a concern, especially beyond the reassuring
context of RCTs [68]. Indeed, in real life, RAAS blockade is consid-
ered as themain of cause of hospitalizations for hyperkalemia, and
it is estimated that around 10% of patients will develop hyperka-
lemia within the first year after starting RAAS blockade therapy
[74]. CKD patients have a higher risk of hyperkalemia, and this risk
is dependent on the renal function (the lower the eGFR, the higher
the risk), being particularly high in patients with GFR below 30mL/
min/1.73 m2. Diabetes in itself is also a risk of hyperkalemia, as
diabetic patients have hyporeninemic hypoaldosteronism and
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into cells. Other important risk factors for hyperkalemia are
advanced age, heart failure, volume depletion, and concomitantly
use of other drugs interfering with renal excretion of potassium
(for example, trimethoprim or nonsteroidal anti-inflammatory
drugs). The risk will be particularly relevant in patients combining
risks, typically the elderly treated by RAAS inhibitor and anti-
inflammatory agents and suffering from acute diarrhea. The risk
of hyperkalemia is also dependent on the dose of ACE inhibitor or
ARA II [74,75]. The risk profile of acute renal failure mirrors the risk
profile of hyperkalemia and both conditions are frequently con-
comitant. In patients with abnormally high potassium level, it
seems unreasonable to start therapies blocking RAAS. In
RENAAL, including T2DM patients with CKD, the mean potassium
concentration at baseline was 4.6 mmol/L and losartan was asso-
ciated with a mean increase of up to 0.3 mmol/l [76] However,
more than considering a potassium concentration threshold to
start or not RAAS blocking therapy, it seems very important to
monitor potassium in high risk patients and applying preventive
actions [74,75], including the use of potassium binders [77].
Also for safety reasons, the dual RAAS blockade, especially
the combination of ARA II and ACE inhibitors, is not recom-
mended. Their use might be discussed in very specific patients
with uncontrolled massive albuminuria, under the supervision
of a nephrologist [42]. Lastly, because the hemodynamic effect
of RAAS inhibitors, therapy interruption can significantly
increase GFR level, a mirror image of the decline in eGFR
generally observed at the initiation of a RAAS inhibitor. Thus,
stopping ACE inhibitors or ARA II may be discussed in very
specific patients with advanced renal failure (GFR below
20–30 mL/min/1.73m2) with the aim of delaying dialysis [78].
3. Glucose-lowering medications
Most antihyperglycemic medications can be used safely in
patients with mild to moderate CKD. However, several glucose-
lowering agents are either not advised or require dose adjust-
ments inmore advanced CKD [12,79]. Of note, regulations guiding
the use of metformin, the first-line treatment for the pharmacolo-
gical management of T2DM, in patients with stable, moderate
renal dysfunction have become more lenient in recent years and
metformin may be used at half dose in patients with eGFR
between 30 and 45 ml/min/1.73 m2. In the American recommen-
dations, no precise dosages are recommended in cases of renal
impairment, but metformin should not be initiated if eGFR is
below 45 ml/min/1.73 m2. In Europe, the maximum daily metfor-
min recommended dose is 2000 mg/day in CKD stage 3a
(eGFR = 45–59 ml/min/1.73 m2) and 1000 mg/day in CKD stage
3b (GFR = 30–44 ml/min/1.73 m2). There is agreement upon the
fact that metformin must be stopped if eGFR consistently falls
below 30 ml/min/1.73 m2 [80]. Also the concurrent withdrawal
(albeit temporarily) of metformin is recommended when condi-
tions leading to intermittent hypovolemic state are present, cir-
cumstances that also should lead to the transient interruption of
RAAS inhibitors [81].
Intensive glucose control with classical glucose-lowering
agents including metformin and insulin reduces the risk of
albuminuria, but evidence is lacking that it reduces the risk
of relevant clinical renal outcomes, such as doubling of the
serum creatinine level, ESRD, or death from renal disease
during the years of follow-up of the trials [82,83]. Of increasing
interest, some new antidiabetic agents have demonstrated
renoprotective effects, which occurred beyond improvement
of glucose control [26,84] (Table 4).
3.1. SGLT2 inhibitors
SGLT2is exert their glucose-lowering effects by promoting
glucosuria, an effect resulting also in body weight and fat
mass reduction. Aside from these effects, they increase natriur-
esis and osmotic diuresis, thus reducing arterial blood pres-
sure and plasma overload [85]. SGLT2 inhibitors certainly
represent the most promising pharmacological class among
glucose-lowering agents not only for cardiovascular but also
renal protection in T2DM patients. Numerous excellent and
extensive reviews were devoted to this topic in recent years,
which summarized the preclinical and clinical data and pro-
vided several hypotheses to explain the nephroprotective
effects of these new antidiabetic agents [18,19,21,86–90].
Effects of SGLT2is on the kidney are likely explained by multi-
ple pathways, beyond the systemic effects via reductions in
blood glucose, body weight and blood pressure. SGLT2is are
associated with a reduction in glomerular hyperfiltration, an
effect that is mediated through increased natriuresis and
restored tubuloglomerular feedback, and independent of gly-
cemic control (Figure 1). In addition, they may improve renal
oxygenation and cellular energy metabolism [21] and also
reduce intrarenal inflammation [91], thereby slowing the pro-
gression of kidney function decline.
Because of their specific mechanism of action targeting the
kidney, SGLT2is lose part of their glucose-lowering activity
when eGFR falls below 45–60 ml/min/1.73 m2. Therefore, the
use of SGLT2is is currently not recommended below this
threshold [92,93], yet further studies may mitigate this restric-
tion in the future. Indeed, blood pressure lowering effect of
SGLT2is seems to be maintained [94,95] and a reduction in
major cardiovascular events and mortality was reported in
subgroups analyses of T2DM patients with eGFR below
60 ml/min/1.73 m2 in cardiovascular outcome trials [96,97].
Even if SGLT2is consistently reduce systolic blood pressure
[98], this specific effect seems to play a minor role in the
improvement of renal outcomes in T2DM patients with well-
controlled blood pressure at baseline [99].
In patients with T2DM at high cardiovascular risk recruited
in EMPA-REG OUTCOME, empagliflozin was associated with
slower progression of CKD, reflected by reduction in albumi-
nuria and less decline in eGFR, and lower rates of clinically
relevant renal events, including progression to ESRD, than was
placebo when added to standard care (Table 4) [22].
A detailed post-hoc analysis supported short-term and long-
term benefits of empagliflozin on UACR, irrespective of
patients’ albuminuria status at baseline [100]. Of note, the
reductions in major cardiovascular events and mortality were
also consistent across categories of eGFR and UACR at base-
line [96].
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In the Canagliflozin Cardiovascular Assessment Study
(CANVAS) Program, prespecified composite endpoint of sus-
tained and adjudicated doubling in serum creatinine, ESRD,
or death from renal causes occurred less frequently in the
canagliflozin group compared with the placebo group, with
consistent findings across prespecified patient subgroups
[23]. Annual eGFR decline was slower and mean UACR
was lower in participants treated with canagliflozin than
in those treated with placebo. After a rather short median
follow-up of 2.4 years, only a numerical trend for less
progression to ESRD requiring renal replacement therapy
was noticed (Table 4) [23]. Renal outcomes (HR, 0.59; 95%
CI, 0.44–0.79 versus HR, 0.63; 95% CI, 0.39–1.02; interaction
p value = 0.73) were similarly reduced in the secondary and
primary cardiovascular prevention cohorts of CANVAS,
respectively [101]. Furthermore, relative effects on most
cardiovascular and renal outcomes were similar across
eGFR subgroups [97].
In the DECLARE (‘Dapagliflozin Effect on CardiovascuLAR
Events’) TIMI 58 cardiovascular outcome trial [102],
a prespecified renal event (including cardiovascular death)
occurred in 4.3% in the dapagliflozin group and in 5.6% in
the placebo group (HR 0.76; 95% CI, 0.67–0.87) [103]. When
the analysis excluded cardiovascular death (which was not
affected by the treatment), the difference in the prespecified
renal composite endpoint (40% decrease in eGFR, ESRD, or
renal death) was even more important: HR 0.53 (0.43–0.66). No
significant interaction (p = 0.87) was detected when the ana-
lysis was performed according to baseline eGFR levels, with
less events in the dapagliglozin groups versus the placebo
groups: < 60 ml/min/1.73 m2 (n = 606 vs. n = 659) HR 0.60
(0.35–1.02); eGFR 60 to < 90 ml/min/1.73 m2 (n = 3838 vs.
3894): HR 0.54 (0.40–0.73); eGFR ≥ 90 ml/min/1.73 m2
(n = 4137 vs. n = 4025): HR 0.50 (0.34–0.73). Acute kidney
injury occurred less frequently in the dapagliflozin group than
in the placebo group (1.5% vs. 2.0%; HR 0.69 (0.55–0.87),
p = 0.002) [103]. Of note, in DECLARE-TIMI 58, less patients
with eGFR < 60 ml/min/1.73 m2 (7.4%, in fact a predefined
exclusion criterion, but not always respected by the investiga-
tors) were recruited than in EMPA-REG OUTCOME (26 %) and
CANVAS (20%), which allowed recruitment of patients pro-
vided that eGFR was > 30 ml/min/1.73 m2).
It is noteworthy that EMPA-REG OUTCOME, CANVAS, and
DECLARE-TIMI 58 were cardiovascular outcome RCTs, with
renal outcomes as secondary rather than primary endpoints,
even if prespecified. According to a recent meta-analysis, the
results regarding renal protection using the composite end-
point of renal worsening, ESRD, and renal death were remark-
ably consistent in the three trials and comparable in patients in
secondary cardiovascular prevention (HR 0.56; 0.47–0.67) and
primary cardiovascular prevention (HR 0.54; 0.42–0.71) [104].
The magnitude of benefit of SGLT2is varied with baseline
renal function, with lesser reductions in progression of renal
disease (p for interaction = 0.0258) but greater reductions in
hospitalizations for heart failure (p for interaction = 0.0073) in
patients with more severe kidney disease at baseline. These
data should be confirmed in dedicated renal outcome trials
such as three ongoing large prospective RCTs, CREDENCE
(“Canagliflozin and Renal Endpoints in Diabetes with
Established Nephropathy Clinical Evaluation [105] EMPA-
KIDNEY (The Study of Heart and Kidney Protection With
Empagliflozin: Clinical Trials.gov Identifier: NCT03594110)and
Dapa-CKD (A Study to Evaluate the Effect of Dapagliflozin on
Renal Outcomes and Cardiovascular Mortality in Patients With
Chronic Kidney Disease: ClinicalTrials.gov Identifier:
NCT03036150).
Even if SGLT2is offer nephroprotection (together with cardio-
protection), they may also be associated with adverse effects,
including an increased risk of acute kidney injury [106], so that an
individual benefit-risk balance should be taken into consideration
[107,108]. Several mechanisms have been proposed to explain
a risk of acute kidney injury with SGLT2is: effective volume deple-
tion (dehydration, diuretic therapy), excessive decline in trans-
glomerular pressure (concomitant RAAS blockade), induction of
renal medullary hypoxic injury (for instance, triggered by nonster-
oidal anti-inflammatory drugs) [108]. Combining these three con-
ditions, which may act synergistically, would dramatically increase
the risk of acute renal failure. A higher proportion of reports with
acute renal failure were collected among reports with SGLT2is in
the FDA adverse event report system (FAERS) database [109]. As
a consequence, the Food and Drug Administration (FDA) now
requires that acute kidney injury be listed as a potential side effect
of the SGLT2is along with cautious prescription of these glucose-
lowering agentswith othermedications, such as RAASantagonists,
diuretics, and nonsteroidal anti-inflammatory drugs. It is impera-
tive to ascertain whether the reported acute renal failure repre-
sents true structural kidney injury or only a functional decline in
glomerular filtration rate [110]. Of note, the recent data of the
DECLARE-TIMI 58 trial are reassuring to this respect, with less
cases of renal impairment in the dapagliflozin group than in the
placebo group, despite 81.3% of patients were treated with RAAS
inhibitors at baseline [103].
Another dreaded adverse event that has been associated with
SGLT2use is lower-limbamputation. In a recent extensive systema-
tic review, there are strong overall associations of SGLT2 inhibition
with protection against serious decline in kidney function (RR 0.59,
95% CI 0.49–0.71), besides major cardiovascular events, heart fail-
ure and all-cause death. However, SGLT2 inhibitors were asso-
ciated with amputations (RR 1.44, 95% CI 1.13–1.83), aside of well-
known adverse events such as genital infections and volume
depletion effects [111]. According to this review, this association
with amputation appears to differ between individual SGLT2 inhi-
bitors, with a higher risk for canagliflozin [111], a difference mainly
driven by the results of CANVAS [112]. This increased risk of lower
limb amputation was also observed in some observational studies
and pharmacovigilance reports, yet whether it is a class effect or
not remains an open question [113]. Of note, patients with ESRD
who receive dialysis are at high risk of lower extremity amputation,
which is associated with a high mortality rate, and among those
people with ESRD, patients with diabetes had amputation rates
more than five times as high as patients without diabetes [114].
3.2. GLP-1 receptor agonists
GLP-1RAs act on traditional risk factors for progressive kidney
disease including improved glucose control, blood pressure
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lowering, insulin-sparing effect and body weight reduction.
Furthermore, GLP-1RAs can also have direct effects in the
kidney (review in [25] and [115]). However, the mechanisms
that may underlie any direct actions in the kidney remain to
be established and might be multiple: effects on the intrarenal
RAAS, ischemia/hypoxia, apoptosis, and neural signaling.
Furthermore, GLP-1RAs have also been shown to reduce
inflammation, macrophage infiltration, oxidative stress, and
the accumulation of type 4 collagen in the kidney [25,115].
The GLP-1 receptor is expressed in glomeruli and arterioles,
yet kidney protective actions independent of the GLP-1 recep-
tor have also been proposed. GLP-1 induces natriuresis by
reducing Na/H exchange transporter isoform 3-dependent
sodium reabsorption in the proximal tubule [25].
In cardiovascular outcome trial LEADER, the prespecified
secondary renal outcome was a composite of new-onset per-
sistent macroalbuminuria, persistent doubling of the serum
creatinine level, end-stage renal disease, or death due to
renal disease [24]. After a median follow-up of 3.84 years in
T2DM patients at high risk of cardiovascular disease, this renal
outcome occurred in fewer participants in the liraglutide
group than in the placebo group (HR 0.78; 95% CI, 0.67–0.92;
p = 0.003) (Table 4). This result was driven primarily by the
new onset of persistent macroalbuminuria, whereas no signif-
icant differences were noticed for persistent doubling of the
serum creatinine level, end-stage renal disease, or death due
to renal disease (Table 4). The rates of renal adverse events
were similar in the liraglutide group and the placebo group
(15.1 events and 16.5 events per 1000 patient-years), including
the rate of acute kidney injury (7.1 and 6.2 events per 1000
patient-years, respectively) [24].
In SUSTAIN-6, after a median follow-up of 2 years, new or
worsening nephropathy occurred less frequently in T2DM
patients treated with semaglutide (HR = 0.64; 95% CI 0.46–
0.88; p < 0.01). However, as in LEADER, this composite out-
come was largely driven by a reduction in new-onset macro-
albuminuria, whereas doubling of serum creatinine
concentration to an eGFR ≤ 45 ml/min per 1.73 m2, ESRD,
and death of renal cause were unaffected (Table 4) [116]. In
EXSCEL, a reduction of new-onset macroalbuminuria (2.2% vs.
2.8%; P = 0.03) was also reported in patients treated with once
weekly exenatide compared with placebo, without significant
changes neither in microalbuminuria (7.2 vs. 7.5%) nor in ESRD
requiring replacement therapy (0.7 vs. 0.9%) after a median
follow-up of 3.2 years [117]. ELIXA recruited T2DM patients
who had had a recent acute coronary event and a eGFR >
30 ml/min/1.73 m2 (mean value 76) [118]. Baseline character-
istics showed that 74.3% of patients had normoalbuminuria,
19.2% microalbuminuria and 6.5% macroalbuminuria.
A modest reduction in the increase in albuminuria was
observed after 24-month treatment with lixisenatide com-
pared with placebo (+ 24% vs. + 34 %, p = 0.004, but
p = 0.07 after adjustment for HbA1c) [118]. In HARMONY-
OUTCOMES, T2DM patients with established cardiovascular
disease treated with albiglutide showed significantly less car-
diovascular complications than those treated with placebo
[119]. Around 19% of patients had diabetic nephropathy at
baseline, yet mean eGFR averaged 79 ml/min/1.73 m2 and no
data on albuminuria were reported. A slight reduction in eGFR
was noticed in the albiglutide group compared with the pla-
cebo group, significant at 8 months but not anymore at
16 months (Table 4). Renal events were not analyzed as an
efficacy but a safety outcome. Renal impairment (not precisely
defined) trended to occur less frequently in patients treated
with albiglutide than in patients having received placebo (6 vs.
7%) (Table 4).
Integrated data from 9 phase 2 and 3 trials in T2DM patients
(N = 6005) showed that dulaglutide did not affect eGFR, but
slightly decreased UACR, without increasing kidney adverse
events, when compared to placebo or active comparators
[120]. In the 52-week AWARD-7 trial in patients with T2DM and
moderate-to-severe CKD, once-weekly dulaglutide produced
glycemic control similar to that achieved with insulin glargine,
no greater reduction in UACR, but significantly reduced decline
in eGFR (p = 0.005 for dulgalutide 1.5 mg and p = 0.009 for
dulaglutide 0.75 mg vs. insulin) [121]. Overall these short-term
data suggest that dulaglutide has the potential to exert renal
protection in patients with T2DM, an effect that should be con-
firm in long-term studies with clinical hard endpoints [122].
Divergent results were reported in recent meta-analyses
that investigated the effects of GLP-1RAs on microvascular
and renal complications [123–125]. Thus, even if most studies
report beneficial effects of GLP-1RAs on the incidence of
albuminuria, more evidence is needed to convincingly support
positive effects on renal function and progression to ESRD in
patients with T2DM.
4. Other pharmacological agents in development
Considering the complex pathophysiology of CKD in T2DM
and the residual renal risk despite RAAS inhibition, even
when some new glucose-lowering agents with proven reno-
protective properties are added, there is still room for inno-
vative strategies. Whereas classical approaches targeted
intrarenal hemodynamic abnormalities, new approaches
focus on the potential to reduce fibrosis, low-grade inflam-
mation, oxidative stress, advanced glycation end products
(AGE), all processes involved in renal failure in T2DM [22].
Table 5 summarizes new therapies tested in humans at
different stages of development and in-depth reviews on
this topic may be found elsewhere [8,126–130]. In phase 2
trials, most agents showed their ability to reduce albumi-
nuria and may also exert some protection on eGFR decline,
but these effects were not yet confirmed in phase 3 trials for
many of them. Of note, some promising drugs tested in
large RCTs gave negative results or were associated with
adverse events [131]. Globally, confirming safety remains
a priority before use in clinical practice. Some concerns
exist, for example, with endothelin receptor antagonist
(fluid overload and heart failure, especially with avosentan
whose development has been stopped, whereas the efficacy
and safety of another compound atrasentan is currently
investigated in the ongoing SONAR trial) [132], or bardox-
olone (more cardiovascular events and worse albuminuria)
[131]. Overall, for all these pharmacological interventions,
the nephroprotective efficacy was mainly speculative and
remains largely unproven.
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5. Conclusions
Diabetic kidney disease becomes increasingly prevalent
among patients with T2DM and is associated with increased
mortality, decreased quality of life and high healthcare cost.
Thus preventing early CKD in T2DM patients and limiting the
progression toward ESRD are major challenges in clinical prac-
tice. Besides healthy lifestyle and the avoidance of nephrotoxic
agents, it is essential to maintain adequate control of blood
glucose and blood pressure as both chronic hyperglycemia
and hypertension exert deleterious effects on kidney structure
and function. RAAS inhibitors were the first drugs that have
proven their efficacy to prevent surrogate and hard clinical
renal outcomes, independently of their antihypertensive
effects. Their ability to control albuminuria/proteinuria beyond
the reduction of blood pressure appears of major importance.
In all guidelines, they are recommended in T2DM patients
with any stage of CKD, from very early stage to more
advanced disease, that is 3 to 4 stages CKD, especially if
(micro)albuminuria is present. Overall, ACE inhibitors and
ARA II are considered to exert equal renoprotective effects.
New glucose-lowering agents, GLP-1RAs and especially
SGLT2is, have recently shown nephroprotective properties on
composite renal outcomes combining surrogate endpoints
(albuminuria, eGFR decline) and hard clinical events (progres-
sion to ESRD requiring renal replacement therapies). These
effects were observed when added to standard care, including
RAAS blockers, in T2DM patients with established or at high risk
of cardiovascular disease. The nephroprotection by SGLT2is
occurs independently of glucose control and this observation
opens new perspectives for the treatment on nondiabetic CKD
currently in investigation. Whether SGLT2is also exert nephro-
protection in T2DM patients with more advanced stages of the
disease (stages 3b–4 CKD) remains to be carefully investigated
in dedicated studies with renal outcomes as primary endpoints,
as well as the complex and pleiotropic underlying mechanisms
contributing to renoprotection.
Finally, despite the favorable effects of these pharmacolo-
gical approaches, even if combined, the renal residual risk
remains high in many T2DM patients. Therefore, new therapies
are in development targeting fibrosis, low-grade inflammation,
oxidative stress or AGE deposition, all processes involved in
progressive renal impairment in T2DM. However, despite some
promising results, all these new drugs first have to prove both
their efficacy and safety in large RCTs before any future use in
clinical practice.
6. Expert opinion
In parallel with the T2DM pandemic, CKD related to diabetes
has become the leading cause of ESRD in many countries
worldwide, and is associated with high cardiovascular morbidity
and mortality. Based on landmark clinical trials, diabetes-related
CKD is preventable by controlling conventional factors, mainly
hyperglycemia and hypertension, with multifactorial therapies
combining lifestyle and drug interventions. Many antidiabetic
medications (metformin, glitazones, DPP-4 inhibitors) have
shown promising results in animal models of CKD and offered
the possibility to investigate potential molecular mechanisms
that may explain renoprotection. However, although useful,
these animal models are not perfect [133], so that preclinical
data should be confirmed in well-designed clinical studies. For
all these antidiabetic agents, only effects on biomarkers and
soft surrogate endpoints such as reduction of albuminuria and
more rarely reduction in eGFR have been reported [83].
Table 5. Innovative therapies to prevent or retard the progression of chronic kidney disease in T2DM. Of note, promising
preliminary results were not always confirmed because of poor efficacy or safety reasons. See reviews in [8,126–130].
Anti-fibrotic effects
PKC (protein kinase C) inhibitors Ruboxistaurin
Glycosaminoglycans Sulodexide
Anti-TGF (transforming growth factor) FG-3019, pirfenidone, LY2382770, LY3016859
Metalloprotease inhibitors XL 784, doxycycline, minocycline
Serotonin receptor antagonists Sarpogrelate
Anti-inflammatory effects
Phosphodiesterase inhibitors Pentoxifylline, CPT-499, PF-00489791
Janus kinase inhibitors Baricitinib
Endothelin receptor antagonists Avosentan, atrasentan, dagutril
Chemokine inhibitors CCX140-13, PF-04634817, BMS-813160
Bindarit, Emapticap pegol
Anti-oxidant effects
Activation of Nrf2 pathway Bardoxolone
Inhibitors of NADPH oxidase 1 and 4 GKT-137831
α-Lipoic acid (+ losartan) INV-144
Reduction of oxidative stress, reduction of Ox-LDL Probucol
Pleiotropic effects, activation of Nrf2 pathway Silymarin




Multiple effects Cholecalciferol, paricalcitol, calcitriol, and α-calcidol
AGEs: advanced glycation end products
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A biomarker is an objectively measured characteristic that is
indicative of some underlying phenomenon or process (i.e.
albuminuria), while a surrogate is a biomarker that ‘takes the
place’ of a clinically meaningful outcome, usually earlier in the
disease process (i.e. reduction in eGFR) [134]. Even, if changes in
albuminuria and eGFR were associated with a greater risk of
experiencing clinical outcomes [135], clinicians are waiting for
clear-cut data on more relevant hard endpoints, such as avoid-
ing the progression to ESRD or renal death. Some well-known
agents (RAAS inhibitors) and, more recently, new antidiabetic
medications (SGLT2is) have shown renoprotective effects, not
only on surrogate endpoints but also on hard clinical outcomes,
independently of their blood pressure-lowering activity and
glucose-lowering activity, respectively. However, even if com-
bined therapy is used, the remaining risk of CKD progression in
T2DM patients is still high.
Direct comparison of agents within a pharmacologic class
or between drug classes is hazardous, as renal outcomes are
inconsistently defined across trials. As a consequence, the
impact of many specific drugs on renal outcome measures in
patients with T2DM remains unclear. The evaluation of hard
clinical outcomes such as progression to ESRD or death of
renal cause requires a long follow-up in large cohorts. As it is
hard to carry out and finance such studies, most recent pub-
lications use composite renal outcomes, a mix of surrogate
and hard endpoints, which, however, may differ across RCTs
(Table 1–4). Of note, these composite endpoints can reveal
significant results driven by a single surrogate marker, for
instance reduction in albuminuria, but not clinical events of
true relevance to T2DM patients, for instance need for renal
replacement therapy. Renal outcome studies including a well-
defined, standardized core set of patient-relevant outcomes
are needed to achieve evidence-based guidance and improve
clinical care for T2DM patients at risk of CKD [136,137].
A doubling of serum creatinine level is generally used in
most studies either as individual endpoint or as part of
a composite outcome. However, it is a rather late event in
CKD natural history, corresponding to a change in eGFR of
more than 50%. There is great interest in considering alter-
native endpoints for clinical trials to shorten their duration,
reduce sample size, and extend their conduct to patients with
earlier stages of CKD. A 30% declines in eGFR over 2 years
occurred more commonly than a doubling of serum creatinine
concentration and was strongly and consistently associated
with the risk of ESRD and mortality [138]. A scientific workshop
sponsored by the National Kidney Foundation and the US FDA
concluded that a confirmed decline in eGFR of 30% over 2–
3 years may be a valuable alternative surrogate end point for
CKD progression in most circumstances [139]. Another chal-
lenge is to improve clinical trial enrolment criterion to identify
T2DM patients at higher risk of ESRD [140]. This improvement
will be crucial to reduce the sample size and ameliorate the
statistical power by increasing the number of key events in
RCTs. It will also be of major importance in clinical practice to
more effectively select T2DM patients who should require
intensive combining therapy for a better renal protection.
RAAS inhibitors and SGLT2 inhibitors are the two pharmaco-
logic classes that have best proven to improve both surrogate
and hard clinical endpoints in patients with T2DM. RAAS inhibi-
tors were initially developed as antihypertensive agents, yet they
renoprotective effects appear to be at least partially independent
of their blood pressure lowering effects. These agents also
reduce proteinuria, a risk marker for renal disease progression
[70] and accumulating evidence indicates that their antiprotei-
nuric effect correlates with their additional renal benefits [71].
High dosing of ACE inhibitors or ARA II may be a valuable
approach for providing greater reduction in proteinuria and
ultimately renoprotection [72]. Similarly, SGLT2 inhibitors were
developed as antihyperglycemic agents, yet their nephroprotec-
tion is essentially independent of their glucose-lowering effects.
Both pharmacological classes modify intrarenal hemodynamic
properties by complementary mechanisms contributing to
reduce intraglomerular pressure [141,142] (Figure 1). RAAS inhi-
bitors, by inhibiting vasoconstrictive effects of angiotensin 2,
dilate postglomerular artery whereas SGLT2 inhibitors, by restor-
ing tubuloglomerular feedback, constrict preglomerular artery.
Intriguingly, experimental studies in rats suggested that dapagli-
flozin-associated beneficial effects on diabetic nephropathy
might result from suppression of renal RAAS component expres-
sion, contributing to reduction in oxidative stress and interstitial
fibrosis [143]. In hypertensive patients with T2DM on stable RAAS
blocker therapy, dapagliflozin significantly reduced albuminuria,
a reduction that remained present after adjusting for changes in
HbA1c, systolic blood pressure, body weight and eGFR [144].
However, T2DMpatients who did not respond to RAAS inhibition
by a reduction in albuminuria also did not respond to dapagli-
flozin, indicating that individual therapy resistance to RAAS inhi-
bition cannot be overcomewith the addition of SGLT2 inhibitors.
These data suggest that the individual drug resistancemay be an
intrinsic individual characteristic unrelated to the type of phar-
macologic intervention, unless the mode of action of the SGLT2
inhibitor on albuminuria is through the RAAS [145]. Of note, in
both EMPA-REG OUTCOME and CANVAS, almost three-quarters
of T2DM patients were treated with RAAS inhibitors at baseline
and throughout the trials. Subgroup analyses showed no signifi-
cant interaction between users and non-users of RAAS blockers
regarding primary cardiovascular composite endpoints and car-
diovascular death both in EMPA-REG OUTCOME [146] and in
CANVAS [112]. No such subanalysis is reported in DECLARE-
TIMI 58 [103] neither for renal outcomes yet. Both RAAS inhibi-
tors and SGLT2 inhibitors are renoprotective, but may also exert
deleterious effects leading to acute kidney insufficiency in certain
circumstances, such as dehydration and association with
nonsteroidal anti-inflammatory agents [106,110,147]. As
a consequence, caution and appropriate supervision should be
recommended when using these agents in more frailty patients,
for instance elderly patients. Whereas RAAS blockers may induce
hyperkalemia, as previous discussed, SGLT2 inhibitors are gen-
erally not associated with ionic disturbances.
The effects of empagliflozin [96] and canagliflozin [97] on
cardiovascular and renal outcomes were not modified by base-
line level of kidney function in T2DM patients with a history or
high risk of cardiovascular disease down to eGFR levels of 30mL/
min/1.73 m2. Thus, reassessing current limitations on the use of
SGLT2 inhibitors in patients with CKD at high risk of cardiovas-
cular disease may allow additional individuals to benefit from
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this therapy. Furthermore, the glucose-independent hemody-
namic intrarenal mechanisms of SGLT2 inhibitors provide the
possibility to extend the use of these medications to non-
diabetic kidney disease. This should be confirmed in ongoing
dedicated trials. If results were positive, they will have the poten-
tial to change clinical practice and outlook of high-risk patients
with diabetic and nondiabetic CKD.
Because of the beneficial effects of SGLT2 inhibitors not
only on surrogate endpoints but also on hard renal outcomes
(in contrast to what has been shown with GLP-1RAs) [148], the
recent consensus report by the American Diabetes Association
(ADA) and the European Association for the Study of Diabetes
(EASD) considers that SGLT2 inhibitors with evidence of redu-
cing CKD in cardiovascular outcome trials should be consid-
ered as the best pharmacological option to be added to
metformin in T2DM patients with CKD, provided that eGFR is
adequate. If SGLT2 inhibitors are not tolerated or contraindi-
cated or if eGFR is less than adequate, the addition of a GLP-
1RA with proven cardiovascular benefit may be consid-
ered [149].
The economic burden of progressive CKD among T2DM
patients is high [150]. Whether new pharmacological approaches
currently in development will succeed to reduce the residual risk
of CKD in T2DM patients remains an open question. The future
challenge will be to find combined pharmacological therapies
offering the best renal (and cardiovascular) protection, with
a good safety profile and at a reasonable cost.
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